Table 3. SAQ Measurements During the Entire Study.
Outcome Measure | DAM (n = 99) | NAM (n = 99) | SA (n = 101) | WL (n = 99) | P Value | Value of Pairwise Comparison | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
DAM vs NAM | DAM vs SA | DAM vs WL | |||||||||
Effect Size (95% CI) | P Valuea | Effect Size (95% CI) | P Valuea | Effect Size (95% CI) | P Valuea | ||||||
Physical limitation score, mean (SD) | |||||||||||
Baseline | 54.21 (13.89) | 55.33 (13.51) | 54.63 (12.69) | 54.64 (12.45) | .95 | NA | NA | NA | NA | NA | NA |
Treatment for 1-4 wk | 58.41 (12.29) | 58.44 (10.87) | 56.54 (12.11) | 55.37 (11.58) | .20 | NA | NA | NA | NA | NA | NA |
After treatment, wk | |||||||||||
5-8 | 60.58 (9.79) | 59.31 (9.73) | 57.26 (11.50) | 56.17 (11.04) | .02 | 0.13 (−0.15 to 0.41) | .41 | 0.31 (0.03 to 0.59) | .03 | 0.42 (0.14 to 0.70) | .005 |
9-12 | 60.54 (9.60) | 58.71 (9.95) | 57.07 (11.54) | 56.95 (11.11) | .07 | NA | NA | NA | NA | NA | NA |
13-16 | 62.07 (10.11) | 59.20 (9.60) | 57.37 (11.68) | 55.68 (10.61) | <.001 | 0.29 (0.01 to 0.57) | .07 | 0.43 (0.15 to 0.71) | .002 | 0.62 (0.33 to 0.90) | <.001 |
Angina stability score, mean (SD) | |||||||||||
Baseline | 48.48 (17.06) | 48.48 (19.17) | 49.01 (18.00) | 46.72 (16.62) | .81 | NA | NA | NA | NA | NA | NA |
Treatment for 1-4 wk | 86.96 (15.50) | 73.67 (23.00) | 64.90 (24.98) | 54.26 (22.49) | <.001 | 0.68 (0.39 to 0.96) | <.001 | 1.06 (0.76 to 1.35) | <.001 | 1.69 (1.36 to 2.01) | <.001 |
After treatment, wk | |||||||||||
5-8 | 72.55 (24.88) | 60.75 (26.94) | 60.97 (23.56) | 56.38 (20.72) | <.001 | 0.46 (0.17 to 0.74) | .001 | 0.48 (0.19 to 0.76) | <.001 | 0.71 (0.42 to 0.99) | <.001 |
9-12 | 69.44 (23.64) | 53.49 (24.34) | 56.89 (22.07) | 58.24 (22.42) | <.001 | 0.66 (0.38 to 0.95) | <.001 | 0.55 (0.26 to 0.83) | <.001 | 0.49 (0.20 to 0.77) | .001 |
13-16 | 70.83 (23.18) | 55.98 (21.41) | 52.58 (22.39) | 53.23 (20.27) | <.001 | 0.67 (0.38 to 0.95) | <.001 | 0.80 (0.51 to 1.09) | <.001 | 0.81 (0.52 to 1.09) | <.001 |
Angina frequency score, mean (SD) | |||||||||||
Baseline | 68.89 (9.99) | 67.47 (11.72) | 69.21 (11.20) | 67.68 (11.50) | .61 | NA | NA | NA | NA | NA | NA |
Treatment for 1-4 wk | 77.61 (8.82) | 74.36 (8.87) | 72.32 (10.77) | 69.26 (11.85) | <.001 | 0.37 (0.09 to 0.65) | .03 | 0.54 (0.25 to 0.82) | <.001 | 0.80 (0.51 to 1.09) | <.001 |
After treatment, wk | |||||||||||
5-8 | 80.54 (9.99) | 75.59 (10.47) | 73.78 (10.80) | 69.79 (12.27) | <.001 | 0.48 (0.20 to 0.76) | .002 | 0.65 (0.36 to 0.93) | <.001 | 0.96 (0.66 to 1.25) | <.001 |
9-12 | 83.00 (10.43) | 75.27 (9.04) | 74.49 (11.04) | 70.96 (11.46) | <.001 | 0.79 (0.50 to 1.08) | <.001 | 0.79 (0.50 to 1.08) | <.001 | 1.10 (0.80 to 1.39) | <.001 |
13-16 | 84.11 (11.01) | 75.76 (10.40) | 75.36 (11.19) | 70.97 (12.25) | <.001 | 0.78 (0.49 to 1.07) | <.001 | 0.79 (0.50 to 1.07) | <.001 | 1.13 (0.82 to 1.42) | <.001 |
Treatment satisfaction score, mean (SD) | |||||||||||
Baseline | 57.87 (18.04) | 60.78 (15.99) | 59.70 (15.99) | 58.88 (16.73) | 0.66 | NA | NA | NA | NA | NA | NA |
Treatment for 1-4 wk | 72.25 (12.47) | 69.15 (13.69) | 66.07 (13.34) | 59.26 (15.77) | <.001 | 0.24 (–0.04 to 0.52) | .13 | 0.48 (0.20 to 0.76) | .002 | 0.91 (0.62 to 1.20) | <.001 |
After treatment, wk | |||||||||||
5-8 | 73.08 (12.70) | 67.49 (13.03) | 65.55 (12.56) | 61.33 (12.95) | <.001 | 0.43 (0.15 to 0.71) | .003 | 0.60 (0.31 to 0.88) | <.001 | 0.92 (0.62 to 1.21) | <.001 |
9-12 | 72.94 (11.89) | 67.68 (12.22) | 65.73 (12.56) | 63.45 (11.92) | <.001 | 0.44 (0.15 to 0.72) | .004 | 0.59 (0.30 to 0.87) | <.001 | 0.80 (0.50 to 1.08) | <.001 |
13-16 | 74.44 (12.54) | 66.62 (12.61) | 65.68 (13.23) | 63.19 (13.77) | <.001 | 0.62 (0.33 to 0.90) | <.001 | 0.68 (0.39 to 0.96) | <.001 | 0.85 (0.56 to 1.14) | <.001 |
QoL score, mean (SD) | |||||||||||
Baseline | 42.42 (17.86) | 43.60 (18.09) | 41.75 (15.92) | 43.10 (14.87) | .87 | NA | NA | NA | NA | NA | NA |
Treatment for 1-4 wk | 50.45 (17.00) | 47.43 (18.00) | 45.45 (15.26) | 46.45 (16.28) | .19 | NA | NA | NA | NA | NA | NA |
After treatment, wk | |||||||||||
5-8 | 51.90 (16.16) | 47.31 (17.38) | 46.34 (15.51) | 46.28 (15.73) | .06 | NA | NA | NA | NA | NA | NA |
9-12 | 51.20 (16.12) | 48.39 (16.68) | 47.19 (15.69) | 48.14 (15.22) | .36 | NA | NA | NA | NA | NA | NA |
13-16 | 52.59 (15.18) | 47.83 (16.66) | 48.20 (16.15) | 48.21 (14.00) | .12 | NA | NA | NA | NA | NA | NA |
Abbreviations: DAM, disease-affected meridian; NA, not applicable; NAM, nonaffected meridian; QoL, quality of life; SA, sham acupuncture; SAQ, Seattle Angina Questionnaire; WL, wait list.
Based on the Bonferroni adjustment in pairwise comparison and on analysis of variance.